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NATIONAL ORGAN TRANSPLANT ACT'S
BAN ON BONE MARROW DONATION
COMPENSATION:
LEGAL COMPENSATION TO CREATE A
LIFE, BUT NOT TO SAVE A LIFE
MARY G. VITALEt
INTRODUCTION
In December 2008, Kumud Majumder received devastating
news that most parents would consider to be their worst
nightmare: his eleven-year-old son's leukemia had relapsed.'
Arya Majumder was diagnosed in 2006 with acute lymphoblastic
leukemia ("ALL"), a particularly aggressive cancer of the white
blood cells that predominantly affects children.2 This deadly
disease causes a person's bone marrow to make abnormal,
unformed cells called blasts.3 Blasts typically transform into
' Senior Staff Member, St. John's Law Review; J.D. Candidate, 2012, St. John's
University School of Law; B.S., Boston University, 2009. I would like to thank
Professor Rosa Castello for all her hard work, dedication, and guidance during this
note-writing process. Thank you, also, to Adam Rafsky for being a great Notes and
Comments Editor, to my family and friends for all their support, and to my
wonferful fiance, Mark, for always inspiring me to do my best. This Note is dedicated
in loving memory of my dear friend, Nolan Morales, and all those who have been lost
to leukemia.
A previous draft of this Note was selected for First Prize in the Epstein, Becker,
& Green, P.C. Health Law Writing Competition.
See Complaint for Declaratory and Injunctive Relief at 8, Flynn v. Holder, No.
CV0907772, 2009 WL 3495055 (C.D. Cal. Oct. 26, 2009) [hereinafter Plaintiffs'
Complaint]. Kumud Majumder is one of the plaintiffs in a class action lawsuit
against Eric Holder in his official capacity as Attorney General challenging the
constitutionality of the National Organ Transplant Act as discussed infra in Part
I.B.
2 See Acute Lymphoblastic Leukemia (ALL), NAT'L MARROW DONOR PROGRAM,
http://www.marrow.org/PATIENT/UndrstndDiseaseTreat/LrnaboutDisease/ALL
/index.html (last visited Jan. 28, 2012) [hereinafter NAT'L MARROW DONOR
PROGRAM]. ALL is the most common leukemia in children, however, it can also
appear in adults. Approximately 4,000 new cases of ALL are reported in the United
States every year. See id.
' See id.
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lymphocytes, which are white blood cells that the body uses to
fight infections.4 However, because the blasts are abnormal, they
cannot develop properly to fight infections. Typically, as in
Arya's case, ALL is initially treated with chemotherapy or
radiation therapy.
In Arya's case, while previous treatment with chemotherapy
in 2006 worked, in 2008 Arya's health had rapidly declined' and
he needed an immediate bone marrow transplant if he had any
hope of surviving.8 A bone marrow transplant is considered an
ALL patient's best chance of survival, especially when the cancer
has relapsed and chemotherapy is not likely to provide long-term
remission.'
With no suitable match in sight, Kumud desperately
accepted marrow cells from a "next best match," unrelated donor,
or a partial match donor, in an attempt to save his son's life.'o
This donation resulted in an undesirable match, known as a
rejection,' meaning Arya's body identified the transplant tissue
Id.
' Id. These abnormal cells duplicate extremely quickly and prevent essential,
normal red blood cells from growing. See id.
6 Id.
' See Plaintiffs' Complaint, supra note 1. Arya "began to lose his eyesight and
the cancer invaded his brain and testicles." Id.
* See id.
* See ALL Transplant Outcomes, NAT'L MARROW DONOR PROGRAM,
http://www.marrow.org/PATIENT/UndrstndDiseaseTreat/Lrn aboutfDisease/ALL
/ALLTransplantOutcomes/index.html (last visited Jan. 28, 2012) (showing the
approximate survival rates for ALL patients at various stages of remission who
received bone marrow transplants between 1998 and 2006); see also Maurizio Arico
et al., Outcome of Treatment in Children with Philadelphia Chromosome-Positive
Acute Lymphoblastic Leukemia, 342 NEw ENG. J. MED. 998, 998 (2000) (discussing
how bone marrow transplantation is superior over intensive chemotherapy alone in
prolonging initial complete remissions).
'o See Plaintiffs' Complaint, supra note 1.
n See id. at 9.
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as a foreign invader and destroyed it. 2 Thus, Arya's parents
were forced to continue their search for a donor who was a closer
match.13
During this time, Kumud joined several other parents of
children with cancer as plaintiffs in a class action lawsuit against
the Department of Justice." The plaintiffs of this lawsuit, Flynn
v. Holder, argued that they ought to be legally allowed to offer
compensation to prospective bone marrow donors to encourage
more donors to come forward to increase their chances of finding
a suitable match to save the lives of their dying children."6 The
lawsuit was dismissed by the District Court of California, but
was reversed and remanded by the Ninth Circuit of the United
States Court of Appeals.16  Unfortunately, Kumud's son did not
live long enough to see this legal battle unfold." A suitable bone
marrow donor was not found in time and Arya Majumder passed
away from leukemia in April 2010 at the age of twelve.
Arya's heartbreaking story is one that is unfortunately
repeated every day, year after year in this country. In 2011 more
than 130,000 Americans were diagnosed with a very serious
blood disease, and their best chances for survival will be a bone
" This "rejection" is also known as graft-versus-host disease ("GVHD"). It occurs
when there are significant discrepancies between the bone marrow tissue type of the
donor and that of the host, or recipient, during a bone marrow transplant. These
cells may identify the host's tissues as foreign and reject them. This commonly
occurs when patients receive bone marrow cells from only partially matched donors.
See Mark F. Anderson, Encouraging Bone Marrow Transplants from Unrelated
Donors: Some Proposed Solutions to a Pressing Social Problem, 54 U. PITT. L. REV.
477, 482-83 (1993) (discussing the importance of finding a close match between a
donor and a recipient to avoid rejection during bone marrow transplants); see also
Richard J. O'Reilly, Allogenic Bone Marrow Transplantation: Current Status and
Future Directions, 62 BLOOD 941, 942-44 (1983).
13 See Plaintiffs' Complaint, supra note 1, at 9. "[Tlhe only way to avoid GVHD is
to assure a close match between donor and recipient." Anderson, supra note 12, at
483. Finding a close bone marrow tissue match means that certain proteins found on
the surface of white blood cells and other tissues of the body called Human
Leukocyte Antigens must be the same for the donor and the patient. See id. at 482
n.14.
1 See Plaintiffs' Complaint, supra note 1, at 4.
'6 See generally id.
1o See generally Flynn v. Holder, 665 F.3d 1048, (9th Cir. 2011); Civil Mins.,
Flynn v. Holder, No. 2:09-CV-07772-VBF-AJWX (C.D. Cal. Mar. 12, 2010) (tentative
ruling regarding Defendant's Motion to Dismiss). For a more in depth discussion of
this pending lawsuit see infra Part I.C.
17 Brief of Appellants at 4 n.3, Flynn v. Holder, 665 F.3d 1048 (9th Cir. 2011)
(No. 10-55643), 2010 WL 5854339.
1s See id.
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marrow transplant.19 Currently, there are 7,500 patients
actively searching for bone marrow donors.20  Approximately
1,000 of these patients, like Arya Majumder, will die while
waiting for a bone marrow transplant.2 ' Only 30% of cancer
patients will find an acceptable donor within their own families.2 2
Thus, the majority of these patients are forced to search outside
their families for a suitable bone marrow donor-an
overwhelmingly difficult task when the odds of finding a match
are approximately one in 20,000 to one in 50,000.23 As a result,
60% of patients in need of a bone marrow transplant are not
24 threceiving one, and the process of finding suitable matches is
further frustrated by the fact that only 2% of the American
population is on the national registry for bone marrow matches.25
The importance of bone marrow transplants cannot be
overstated. A cancer patient who receives a transplant can have
19 Resources, MORE MARROW DONORS, http://moremarrowdonors.org/?page
id=87 (last visited Feb. 8, 2012).
20 See id.
21 See id.
22 See id.; see also Claudio Anasetti, The Role of the Immunogenetics Laboratory
in Marrow Transplantation, 115 ARCHIVES PATHOLOGY & LABORATORY MED. 228,
292 (1991) (estimating even a less than thirty percent chance of patients finding a
suitable donor within their immediate family); Anderson, supra note 12, at 484.
23 See Bone Marrow Donation, LIVING DONORS ONLINE!, http://www.
livingdonorsonline.org/marrow/marrow4.htm (last visited Feb. 8, 2012) (further
emphasizing that close matches are essential to a successful transplant to avoid
rejection or GVHD); see also Anderson, supra note 12, at 484 (stating the chances of
any two unrelated people having an acceptable match for all three pairs of relevant
Human Leukocyte Antigens are between one in 100 and one in 1,000,000 depending
on how frequently their antigens occur in the general population).
24 See Anderson, supra note 12, at 487.
25 See Resources, supra note 19. The National Bone Marrow Program was
started by the federal government in 1986 and created a computer file of volunteer
donors whose tissues could be matched with patients in need of bone marrow
transplants. See Anderson, supra note 12, at 485; Who We Are-About the National
Bone Marrow Program and Be the Match, NAT'L MARROw DONOR PROGRAM,
http://www.marrow.org/ABOUT/Who WeAre/index.html (last visited Feb. 8, 2012).
Although the creation of a national registry was an important step that has made a
substantial difference for many cancer patients and their families, it is nowhere near
an aggressive enough approach to ensure that all patients in need receive an
acceptable bone marrow transplant.
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a survival rate as high as 90%;26 without a transplant, death is
almost a certainty because bone marrow transplants are
generally used as a patient's last resort.27
Incentives are desperately needed to encourage more donors
to come forward as the current altruistic-based system of bone
marrow donation is just not working. Allowing modest
compensation for bone marrow donations is the most efficient
way to increase donations, as observed in the areas of blood and
gamete-sperm and egg-donation, 8 and to ensure that patients
receive this life-saving treatment. Generous compensation
persuades thousands of men and women every year to donate
eggs and sperm to infertile couples hoping to conceive a child."
However, similar compensation incentives for bone marrow
donors to save the lives of cancer patients are illegal in the
United States and punishable by up to five years
" See Anderson, supra note 12, at 481. Survival rates often vary by what type of
cancer the patient has in addition to the patient's age and medical history. The
National Marrow Donor Program estimated a national 56.3% one-year survival rate
out of 9,763 bone marrow transplants performed with unrelated matched donors
between 2003 and 2007. See How To Understand Transplant Center Statistics,
NAT'L MARROW DONOR PROGRAM, http://marrow.org/Patient/TransplantPlanning/
Choosing-aTransplantCenter/Things toConsider/How toUnderstand Transplan
t Center Statistics.aspx?terms=how+to+understand+transplant+center+statistics
(last visited Feb. 8, 2012).
27 Anderson, supra note 12, at 481.
28 When the commercial blood market in 1971 was at its height, a pint of blood
sold anywhere from $5 to $30, depending on local conditions. See 1 NAT'L HEART &
LUNG INST., DEP'T OF HEALTH, EDUC., & WELFARE, NHLI's BLOOD RESOURCE
STUDIES: SUPPLY AND USE OF THE NATION'S BLOOD RESOURCE 197 (1972). While
today only a small percentage of blood donors are paid for their services, this change
came about because of a sudden increase in hepatitis in patients transfused with
blood from paid donors who were predominantly from poor areas. Since modern
medicine now has the technology to screen against such diseases, this problem is no
longer an issue and it is extremely likely that a greater emphasis would be placed
back on paid blood donations if today's voluntary system stopped providing enough
blood or blood products to meet the current need. See Anderson, supra note 12, at
492; Sarah Terman, Comment, Marketing Motherhood: Rights and Responsibilities
of Egg Donors in Assisted Reproductive Technology Agreements, 3 Nw. J.L. & Soc.
POL'Y 167, 167 (2008) (discussing how financial incentives have produced
substantial increases in egg donation over the past decade).
29 See Terman, supra note 29; see also CTRS. FOR DISEASE CONTROL AND
PREVENTION, U.S. DEP'T OF HEALTH & HUMAN SERVS., 2007 ASSISTED
REPRODUCTIVE TECHNOLOGY SUCCESS RATES: NATIONAL SUMMARY AND FERTILITY
CLINIC REPORTS 91 (2009) (revealing that over 15,000 embryos created from donor
eggs were used for assisted reproductive procedures). This statistic only refers to
actual embryos successfully created using donor eggs; the additional number of
donated eggs collected in unsuccessful embryo creation, as well as donated eggs
collected for research purposes, are not included in this report.
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in prison.3 0  In 1984, Congress passed The National
Organ Transplant Act ("NOTA"), 42 U.S.C. § 274e, banning
compensation for the donation and receipt of human organs.3 1
This Note argues that this piece of legislation is sorely outdated
and the continued ban on bone marrow donation compensation
no longer serves NOTA's stated purposes. Congress must amend
NOTA to remove bone marrow from the list of human organs
prohibited from being donated for valuable consideration.32 This
amendment will not offend the original purposes of the statute's
enactment and will save the lives of thousands of cancer patients.
Part I of this Note briefly discusses the background of NOTA
and several recent scientific and legal developments in the field
of bone marrow donation. Part II sets forth the policy and legal
arguments for why the continued ban on bone marrow
compensation is illogical, outdated, and possibly even
unconstitutional. As this Note argues, bone marrow donation
differs substantially from the donation of the other organs
included in NOTA's phrasing. In light of recent advances in
biomedical technology since the passage of the statute in 1984,33
making the continued inclusion of bone marrow in NOTA's
definition arbitrary and unnecessary to achieve the statute's
stated purposes. This Note further argues that it is illogical for
Congress to ban compensation for bone marrow cell donation but
allow compensation for other renewable cells, such as eggs,
sperm, and blood. Part III discusses the benefits and potential
problems of three possible solutions to deal with remaining
ethical issues that would exist if Congress were to legalize bone
marrow compensation, and concludes that government regulation
and procurement is the optimal solution.
I. CONGRESS'S STATED PURPOSE FOR NOTA AND RECENT
DEVELOPMENTS IN THE FIELD OF BONE MARROW DONATION
A. Legislative Background of NOTA
The National Organ Transplant Act of 1984 provides that
It shall be unlawful for any person to knowingly acquire,
receive, or otherwise transfer any human organ for valuable
so 42 U.S.C. § 274e (2006 & Supp. I).
3 See id.
3 See id. at § 274e(c)(1).
* See infra Part II.B.
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consideration for use in human transplantation if the transfer
affects interstate commerce. . . . The term "human organ"
means the human (including fetal) kidney, liver, heart, lung,
pancreas, bone marrow, cornea, eye, bone, and skin or any
subpart thereof and any other human organ (or any subpart
thereof, including that derived from a fetus) specified by the
Secretary of Health and Human Services by regulation. 34
NOTA was passed with substantial bilateral support and
little debate,35 primarily in response to moral and ethical
concerns surrounding the advancements in medical technology
made during the 1980s regarding organ transplants.3 6 Congress
maintained that the stated purposes of NOTA were (1) to prevent
the commercialized, permanent disfigurement of the human
body, (2) to prevent the human body from being treated as a
commodity, 37 and (3) to prevent the unjust exploitation of the
poor who may be willing to put their health at risk by selling
their organs.3 8 Moral and ethical concerns over creating a for-
profit market for solid human organs remain prominent in
academia and in the American court system today.3 9
However, Congress specifically excluded renewable cells,
such as blood and semen, from the prohibitions described in
NOTA.40 During its discussion of the statute and subsequent
1 42 U.S.C. § 274e.
" See Patrick D. Carlson, Comment, The 2004 Organ Donation Recovery and
Improvement Act: How Congress Missed an Opportunity To Say 'Yes" to Financial
Incentives for Organ Donation, 23 J. CONTEMP. HEALTH L. & POL'Y 136, 140 (2006);
Lauren R. Siegel, Comment, Re-Engineering the Laws of Organ Transplantation, 49
EMoRY L.J. 917, 934 (2000).
3 See 98 CONG. REC. S14,796-97 (1983) (statements of Sen. Kennedy and Sen.
Heinz) (discussing the moral and ethical concern that a for-profit market in solid
organs would lead to "black-market trafficking in human flesh").
3 See S. REP. No. 98-382, at 7 (1984) ("The committee believes that human body
parts should not be viewed as commodities."); Carlson, supra note 36.
3 See H.R. REP. No. 98-575, pt. 1, at 8 (1983); 98 CONG. REC. S14,698-99 (1983)
(statement of Sen. Tsongas).
3 See Guo Qi Wang v. Holder, 583 F.3d 86, 90-91 & n.3 (2d Cir. 2009) (citing
how a "'scheme to ... sell organs on a black market' is a serious nonpolitical crime"
because of the "general condemnation of this type of behavior by the world
community"); see also Kenneth Baum, Golden Eggs: Towards the Rational
Regulation of Oocyte Donation, 2001 BYU L. REV. 107, 134 (discussing the argument
that allowing a for-profit market of human organs would belittle the human
existence and that the human body is something to be cherished).
40 H.R. REP. NO. 98-1127, at 16 (1984) (Conf. Rep.) ("The term 'human organ' is
not intended to include replenishable tissues such as blood or sperm."); see also J.
Brad Reich & Dawn Swink, You Can't Put the Genie Back in the Bottle: Potential
Rights and Obligations of Egg Donors in the Cyberprocreation Era, 20 ALB. L.J. SCI.
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legislative history, Congress explicitly chose not to include these
cells because they can be replenished and because their donation
"does not compromise the health of the donor."4 '
B. Recent Scientific Developments
Since the passage of NOTA in 1984, there have been several
substantial advances in biomedical technology. One of these
advances that relates directly to bone marrow is the introduction
of the peripheral blood stem cells apheresis ("PBSC") method for
retrieving bone marrow cells from donors.42 PBSC donation was
developed during the early 1990s, after NOTA was drafted.43 In
order to extract bone marrow using the PBSC method, a donor
receives injections of a drug called filgrastim, which moves more
stem, or blood-forming, cells out of the marrow and into the
bloodstream.44 The donor's blood is then removed through a
needle in one arm and passed through a machine that separates
out the blood-forming cells that are needed to treat the
recipient. 45  The remaining blood is returned to the donor
& TECH. 1, 24 (2010) (describing how NOTA prohibits the sale of organs used for
transplant, but does not prohibit valuable consideration of egg cells).
41 S. REP. NO. 98-382, at 16-17 (1984).
42 See Tsutomu Watanabe et al., Autologous and Allogeneic Transplantation
with Peripheral Blood CD34+ Cells: A Pediatric Experience, 84 HAEMATOLOGICA 167,
167 (1999); Donation FAQs, NAT'L MARROw DONOR PROGRAM, http://www.
marrow.org/DONOR/WhenYoureAskedtoDonatefo/DonationFAQs/index.html
(last visited Feb. 9, 2012).
43 See Martin Korbling & Emil J. Freireich, Twenty-Five Years of Peripheral
Blood Stem Cell Transplantation, 117 BLOOD 6411, 6413 (2011) (discussing the
development of peripheral blood stem cell transplantation technology).
44 See Donation FAQs, supra note 43; see also Stem Cell Transplant (Peripheral
Blood, Bone Marrow, and Cord Blood Transplants), AM. CANCER SOC'Y,
http://www.cancer.org/Treatment/TreatmentsandSideEffects/TreatmentTypes/
BoneMarrowandPeripheralBloodStemCellTransplant/stem-cell-transplant-donor-
experience (last visited Feb. 9, 2012) [hereinafter Stem Cell Transplant].
" See Donation FAQs, supra note 43; see also Jonathan L. Powell et al.,
Pediatric Hematopoietic Stem Cell Transplantation, MEDSCAPE REFERENCE, http//
emedicine.medscape.com/article/991032-overview (last updated Sept. 11, 2009); Stem
Cell Transplant, supra note 45.
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through the other arm.46 This process is called asphersis and is
extremely similar to donating blood or plasma," which notably is
not prohibited under the language of NOTA.48
The PBSC donation method is a remarkable breakthrough in
biomedical technology and provides many benefits to both the
donor and the recipient.49  The donor is not required to undergo
anesthesia or multiple marrow aspiration. 0 Furthermore, the
entire process of PBSC only takes approximately two to four
hours," and the risk of a serious side effect is less than one
percent, the same remarkably low risk of serious side effects
seen in blood donors. As for the recipient, the use of PBSC
results in faster engraftment,5 4 which may be associated with a
better clinical outcome." Studies have also shown that the PBSC
method allows for doctors to harvest more stem cells during one
collection than the traditional aspiration method." Additionally,
PBSC has an extremely low rate of infectious complications in
recipients." Because of these benefits, PBSC is now almost
always the preferred method of extracting bone marrow stem
cells.
46 See Donation FAQs, supra note 43; see also Stem Cell Transplant, supra note
45.
47 See Donation FAQs, supra note 43; see also Stem Cell Transplant, supra note
45.
48 See supra notes 41-43 and accompanying text; see also Anderson, supra note
12, at 491 (noting how blood and blood products are excluded from NOTA).
4 See Watanabe et al., supra note 43, at 168.
5 See id. The more traditional, aspiration method of bone marrow extraction
required doctors to sedate donors with anesthesia and then draw out the bone
marrow with a long syringe from the back of the donor's pelvic bone. See Donation
FAQs, supra note 43; see also infra Part II.A.1.
" See Stem Cell Transplant, supra note 45.
52 See Donation FAQs, supra note 43.
3 See Carole Wegner, What Are the Side Effects of Giving Blood?,
LIVESTRONG.COM, http://www.livestrong.com/article/95356-side-effects-giving-blood
(last updated Aug. 11, 2011).
54 This means that the donor's bone marrow tissue is accepted by the recipient's
bone marrow tissue quicker.
* See Watanabe et al., supra note 43, at 168.
56 See id. at 167.
1 See id. at 167-68; see also Jeffrey L. Winters, Complications of Donor
Apheresis, 21 J. CLINICAL APHERESIS 132, 132 (2006) (discussing the extremely low
risk accompanying bone marrow donation).
58 See Watanabe et al., supra note 43; see also Resources, supra note 19 (data
compiled by the Institute of Justice) (stating that the PBSC method is now used in
over seventy percent of marrow donations); Hematopoietic Cell Sources Tailored to
the Patient, NAT'L MARROW DONOR PROGRAM, http://www.marrow.org/
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C. Recent Legal Developments
On October 26, 2009, the Institute of Justice filed a lawsuit
on behalf of several cancer patients and MoreMarrowDonors.org
against Eric Holder in federal district court alleging that NOTA
violates the Equal Protection Clause and the Due Process Clause
of the United States Constitution.5 ' The plaintiffs argued that
NOTA is unconstitutional because it arbitrarily includes bone
marrow on its list of prohibited organs while excluding similar
renewable cells and that the inclusion of bone marrow is not
rationally related to achieve the government's purpose when it
enacted NOTA.o MoreMarrowDonors.org, a plaintiff in the case,
proposed to provide a $3,000 scholarship to individuals found to
be a bone marrow match for a patient in need and whom would
subsequently donate their bone marrow cells to that patient.6 '
The plaintiffs argued that it was absurd that this program is
currently illegal under NOTA.62 On March 12, 2010, the District
Court of California dismissed this case, Flynn v. Holder, for
failure to state a claim." The trial court maintained that the
plaintiffs could not bring an "as applied" equal protection claim
against the government and that the government's purposes for
enacting NOTA were sufficiently legitimate to support the
statute.64
PHYSICIAN/AdvinAutoAlloTx/Hematopoietic-CellSourcesTailindex.html
(last visited Feb. 9, 2012) (showing via chart that between 2002 and 2006 PBSC
donation was used in over 70% of marrow donations for patients over the age of
twenty, compared to only 40% of the time between 1997 and 2001).
5 See Plaintiffs' Complaint, supra note 1, at 2-3; see also John Wagner & Jeff
Rowes, Op-Ed., Give These Donors A Bone, N.Y. TIMES, Jan. 8, 2010, at A27; Sherry
F. Colb, Suit Challenges Federal Ban on Compensation for Bone Marrow Donors,
FINDLAw (Nov. 9, 2009), http://writ.news.findlaw.com/colb/20091109.html.
6o See generally Plaintiffs' Complaint, supra note 1; Wagner & Rowes, supra
note 60; Colb, supra note 60.
61 See Plaintiffs' Complaint, supra note 1, at 27; Saving Lives: Challenging the
Federal Ban on Compensating Bone Marrow Donors, INST. FOR JUST. (Oct. 2009),
http://ij.org/about/2899 [hereinafter Saving Lives].
62 See Plaintiffs' Complaint, supra note 1, at 33-34.
' See generally Civil Mins., Flynn v. Holder, No. 2:09-CV-07772-VBF-AJWX
(C.D. Cal. Mar. 12, 2010) (tentative ruling regarding Defendant's Motion to
Dismiss).
6 See id.
[Vol. 85:12211230
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The Plaintiffs appealed," and on December 1, 2011 the
United States Court of Appeals for the Ninth Circuit reversed
and remanded the district court's ruling.66 The Ninth Circuit
held that the restrictions in NOTA did not prohibit compensation
for bone marrow cells that were donated through PBSC.67 The
court considered such donations to be scientifically "blood
donations" because only the cells found outside the bones flowing
through the veins were being harvested for donation.68 Thus, in
the court's view, bone marrow donated through the PBSC method
was not within the purview of NOTA.69 This ruling is already
being hailed as a victory by the Institute of Justice and cancer
advocates across the nation.70  However, not only is the court's
ruling limited to the states of the Ninth Circuit, the court also
did not address the core constitutional question: whether NOTA's
ban on bone marrow donation compensation as it exists in today's
world violates the Equal Protection Clause." While the Ninth
Circuit's ruling provides some comfort for cancer patients and
their loved ones, an amendment of NOTA is still desparately
needed, as the court's ruling only provides relief for a small
number of states limited to MoreMarrows.org's scholarship
program.
65 See generally Brief of Appellants, Flynn v. Holder, 665 F.3d 1048 (9th Cir.
2011) (No. 10-55643), 2010 WL 5854339.
66 See Flynn v. Holder, 665 F.3d 1048, 1059 (9th Cir. 2011). Attorney General
Eric Holder has since requested a rehearing en banc in this matter. See Appellee's
Petition for Rehearing and Rehearing En Banc at 1, Flynn v. Holder, 665 F.3d 1048
(9th Cir. 2011) (No. 10-55643), 2012 WL 523381.
67 See id.
61 Id. at 1057 ("Such donations of cells drawn from blood flowing through the
veins may sometimes anachronistically be called 'bone marrow donations,' but none
of the soft, fatty marrow is donated, just cells found outside the marrow, outside the
bones, flowing through the veins.").
6 See id. at 1059.
7o Cancer Patients Win Bone Marrow Legal Fight Against U.S. Attorney General,
INST. OF JUST. (December 1, 2011), http://www.ij.org/about/4200.
71 While the Ninth Circuit found that the traditional aspiration method of bone
marrow donation did not violate Equal Protection, the court deemed it unnecessary
to address "any constitutional question" on the subject of PBSC donation. Flynn, 665
F.3d at 1057.
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II. POLICY AND LEGAL ARGUMENTS FOR THE AMENDMENT OF
NOTA
A. The Inclusion of Bone Marrow in NOTA Is Inconsistent with
the Statute's Stated Purposes and Intent
Hardly anything in American society is as it was twenty-six
years ago. This fact is overwhelmingly true in both the fields of
biomedical technology and Congressional legislation. However,
Congress has not given proper consideration to these scientific
changes in regards to several statutes, such as NOTA. Congress
must now amend NOTA to properly reflect these developments in
order to better serve the statute's original purposes and to better
promote the values of justice in today's climate.
This section maintains that the development of the PBSC
method has eradicated many of the ethical concerns Congress
may have had regarding compensation for bone marrow donors.
It further argues that, even without this development, the
inclusion of bone marrow in NOTA's definition is unequivocally
arbitrary because bone marrow is a renewable cell?2 and, as such,
should be excluded from NOTA's ban along with the already
excluded blood, plasma, and gametes.
1. Development of the PBSC Method Renders NOTA's
Inclusion of Bone Marrow Irrelevant to the Statute's Purpose
Biomedical technology has increased so rapidly over the past
decade that medical techniques and procedures doctors used just
a few years ago have become obsolete and outdated. Since the
enactment of NOTA in 1984, scientists, researchers, and doctors
have made astounding technological advancements in the way
diseases are diagnosed and treated.7 3 However, Congress has not
made a single amendment to NOTA, one of the most important
pieces of legislation regulating modern medicine, since the
statute's enactment in 1984." It is crucial for Congress to
advance along with biomedical technology and take notice that
72 See Donation FAQs, supra note 43 (explaining how bone marrow cells are
completely replenished within four to six weeks using either the PBSC method or
the traditional bone marrow aspiration method); Colb, supra note 60.
" See supra Part I.B.
See 42 U.S.C. § 274e (2006 & Supp. 1).
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several of its ethical concerns regarding NOTA are no longer
applicable in the medical community twenty-six years after it
passed this statute.
The development of the PBSC method for bone marrow
extraction has had a profound effect on the way doctors perform
bone marrow transplant procedures. This new method for
extracting bone marrow is a far less invasive and painful
procedure than the traditional aspiration method of extracting
bone marrow that was commonly used during such procedures in
1984.6 During the traditional aspiration method, the doctor
would put the donor under anesthesia while making small
incisions in the back of the donor's pelvic bone. The doctor
would then insert a long syringe through these incisions over the
rear of the pelvic bone to draw out the marrow. While the
traditional aspiration method is also arguably minimally
invasive,7 9 it still carries higher risks than PBSC donation
because of the use of anesthesia.so
Not only does the PSCB method cause patients less pain and
discomfort, it also carries an extremely low chance of serious side
effects and is considered by many doctors to have a very high
success rate.8' Thus, bone marrow donation today does not cause
the donor permanent disfigurement and certainly does not
jeopardize the health and safety of the donor. Arguably, the
biggest sacrifice marrow donors must make during these
procedures is their time and the minimal discomfort they may
experience during injections and extraction. Congress even
shared this opinion when it expressly stated it would not include
plasma and other blood products in NOTA's list of prohibited
organs because the donation procedures used in plasma and
blood donation did "not compromise the health of the donor. "82
As several scholars and researchers have noted, procedures used
for both traditional bone marrow donation and PBSC donation
7 See supra Part I.B.
76 See Watanabe et al., supra note 43, at 168.
71 See Donation FAQs, supra note 43.
78 See id.
7 NOTA's legislative history shows that even Congress noted the difference
between the traditional method of bone marrow donation and other types of invasive
solid-organ donation. See 98 CONG. REC. H6,236 (1984).
so See id.; see also Watanabe et al., supra note 43, at 168.
81 See supra notes 45-51 and accompanying text.
8 S. REP. No. 98-382, at 16-17 (1984).
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practically mirror the methods used in blood and plasma
donation.83  The Ninth Circuit of the United States Court of
Appeals unamimously agreed with this assessment in its recent
ruling in Flynn v. Holder.84
One of Congress's main purposes for drafting and enacting
NOTA in 1984 was to prevent the commercialized, permanent
disfigurement of the human body. 8 It is difficult to argue that
this purpose is not a rational and just governmental concern.
The health and safety of an organ donor should never be
compromised, and Congress correctly guarded this concern by
prohibiting financial incentives that might cause donors to put
their health in jeopardy. However, the inclusion of bone marrow
in NOTA's list of prohibited organs for valuable consideration
does not accomplish this goal. The development of the PBSC
method for extracting bone marrow makes NOTA's inclusion of
bone marrow unnecessary to address the statute's concerns.
Thus, whatever reasons Congress may have had for including
bone marrow no longer exist.
Congress can still protect its interest of preventing
commercialized and permanent disfigurement of the human body
by continuing to ban compensation for donation of the other
organs listed in NOTA-kidneys, livers, hearts, lungs-because
the donation procedures used in those extractions involve major,
invasive surgical procedures that carry a much higher risk for
the donor and the recipient." These organ donation procedures
do involve permanent disfigurement and permanent loss to the
patient and are thus properly included in NOTA. 7 Bone marrow
donation, on the other hand, does not involve permanent
disfigurement or a high risk of harm to the donor. Therefore,
Congress ought to amend NOTA and legalize compensation for
bone marrow transplants.
8 See supra note 48 and accompanying text.
* 665 F.3d 1048, 1052, 1057-59 (9th Cir. 2011).
85 See S. REP. No. 98-382, at 16-17.
' Compare Arthur J. Matas et al., Morbidity and Mortality After Living Kidney
Donation, 1999-2001: Survey of United States Transplant Centers, 3 AM. J.
TRANSPLANTATION 830, 833 (2003) (citing that between 10% and 16.5% percent of
kidney donors experience complications), with Donation FAQs, supra note 43 (citing
that serious complications or side effects occurred in less than 1% of bone marrow
donors).
87 See Anderson, supra note 12, at 478.
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2. Bone Marrow Is a Renewable Cell
Under NOTA, donors are freely allowed to receive
compensation for donating renewable cells, including blood cells
and sperm cells. 8 Because of this, there currently exists capital
markets for several renewable cells, including gametes, blood,
and hair. 9 Congress maintained that these renewable cells
ought to be excluded from NOTA's prohibition because their
donation would not cause the donor to suffer a severe, permanent
loss because such cells would replenish themselves in weeks or
even days after the donation was made.90 Thus, Congress made a
distinction between solid organ donations, such as kidney
donations, and replenishable cell donations," indicating that
Congress did not believe banning compensation for renewable
cells was necessary to achieve NOTA's purpose of preventing the
human body from being treated as a commodity because blood or
gamete donors would not suffer a permanent loss of an organ.
Bone marrow donation is unquestionably more similar to
blood or sperm donation than to kidney or liver donation because
bone marrow cells are also renewable cells." Congressional
committee hearings before the enactment of NOTA document
that even several members of the House Committee on Science
and Technology understood that bone marrow cells are
" See 42 U.S.C. § 274e (2006 & Supp. I); see also H.R. REP. No. 98-1127, at 16
(1984) (Conf. Rep.) ("The term 'human organ' is not intended to include
replenishable tissues such as blood or sperm.").
88 See RUSSELL SCoTT, THE BODY AS PROPERTY 180 (1981) (discussing how
capital markets for human teeth and hair have existed as early as the Elizabethan
era); Margaret R. Sobota, Note, The Price of Life: $50,000 for an Egg, Why Not
$1,500 for a Kidney? An Argument To Establish a Market for Organ Procurement
Similar to the Current Market for Human Egg Procurement, 82 WASH. U. L.Q. 1225,
1236 (2004).
9 See H.R. REP. No. 98-575, pt. 1, at 8 (1983) (indicating that Congress's
concerns over donor health were limited to instances in which the donor suffered a
permanent loss, such as a kidney).
81 See id.
9 See Russell Scott, The Terrible Imbalance: Human Organs and Tissues for
Therapy-A Review of Demand and Supply, 9 J. CONTEMPORARY HEALTH L. & POL'Y
139, 156 (1993) (distinguishing blood and bone marrow-which are vital, regenerative
tissue-from other organs on that basis); Colb, supra note 60 (discussing how
renewable cells do not cause a donor permanent loss and how it is arbitrary for
Congress to treat bone marrow-a proven renewable cell-differently from other
renewable cells, such as blood and gametes); Donation FAQs, supra note 43
(explaining how bone marrow cells are completely replenished within four to six
weeks using either the PBSC method or the traditional bone marrow aspiration
method).
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renewable,9 3 and yet Congress inexplicably still included bone
marrow in the statute. A bone marrow donor loses only
approximately ten percent of their bone marrow cells during a
single collection. 4 This percent of bone marrow, or blood-forming
cells, is completely regenerated by the donor within four to six
weeks of donation." This regeneration happens whether the
marrow is extracted using the traditional bone marrow
aspiration donation method or the PBSC method." Thus,
marrow donors do not experience any type of permanent
disfigurement or loss that kidney or liver donors experience
because bone marrow cells, like blood and sperm, are
regenerative.97
It is completely arbitrary and irrational for Congress to ban
bone marrow donation compensation while simultaneously
allowing for compensation to donors who donate blood or plasma.
Furthermore, because bone marrow cells are renewable, their
inclusion in NOTA's list of organs banned for compensation does
not serve the government interests of preventing the human body
from being treated as a commodity and from preventing
permanent loss to the donor."
B. The Underlying Constitutional Issue: NOTA Violates Equal
Protection
In addition to NOTA being outdated and illogical, its
inclusion of bone marrow has underlying constitutional issues as
well. The inclusion of bone marrow in NOTA's list of organs
banned from donation compensation violates the Equal
Protection Clause because its inclusion is not rationally related
to achieve Congress's stated statutory purposes.
The Supreme Court has held that the Equal Protection
Clause of the Fifth Amendment of the United States Constitution
requires the federal government to provide equal protection of its
laws to all citizens.99 Equal protection cases arise when the
" See Organ Transplants: Hearing Before the Subcomm. on Investigations and
Oversight of the H. Comm. on Sci. & Tech., 98th Cong. 125 (1983).
9 See Anderson, supra note 12, at 482 n.13.
" See id.; see also Donation FAQs, supra note 43.
96 See Donation FAQs, supra note 43.
" See sources cited supra note 93.
" See Carlson, supra note 36.
" See Bolling v. Sharpe, 347 U.S. 497, 500 (1954) (holding that equal protection
applied as much to the federal government through the Fifth Amendment as it did to
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government has enacted a legislative classification that
discriminates against a particular group of citizens by denying
them certain rights or privileges that another group of citizens
is legally allowed to have."oo All equal protection cases pose
the same basic question: Is the government's legislative
classification justified by a sufficient and legitimate purpose? 01
When dealing with a non-suspect class,102 courts are required
to apply rational basis review to determine if a government
classification can withstand an equal protection challenge. 03
Because the Supreme Court strictly limited suspect classes to
those classifications involving race or ethnicity,104 rational basis
review, or minimal scrutiny, is generally thought of as the
"default level" of equal protection review. 0 s
In turning to the constitutionality of NOTA, rational basis
review is the appropriate level of scrutiny because a classification
involving cancer patients is not rooted in race, ethnicity, lawful
resident alienage, or gender. 0 6  Under rational basis review, a
the states through the Fourteenth Amendment); see also ERWIN CHEMERINSKY,
CONSTITUTIONAL LAW: PRINCIPLES AND POLICIES 684-85 (4th ed. 2011); CALVIN
MASSEY, AMERICAN CONSTITUTIONAL LAW: POWERS AND LIBERTIES 608 (3d ed.
2009).
100 See CHEMERINSKY, supra note 100, at 686 (describing that a classification
may be a facially discriminative law or a facially neutral law that has a
discriminatory impact).
101 See id. at 685.
102 A group of citizens classified by some characteristic other than race,
ethnicity, alienage, or gender.
103 See MASSEY, supra note 100, at 608-09; see also Romer v. Evans, 517 U.S.
620, 631 (1996); CHEMERINSKY, supra note 100, at 687-88.
104 See Romer, 517 U.S. at 631; Mass. Bd. of Ret. v. Murgia, 427 U.S. 307, 313
(1976); see also MASSEY, supra note 100, at 640. The Supreme Court also applies
intermediate scrutiny to equal protection challenges involving "quasi-suspect
classes," such as gender or illegitimate birth. See id. at 609; see also Miss. Univ. for
Women v. Hogan, 458 U.S. 718, 724 (1982) (holding that a gender classification fails
unless it is substantially related to a sufficiently important government interest);
Matthews v. Lucas, 427 U.S. 495, 518-19 (1976) (noting that illegitimacy of one's
birth is beyond one's control and that classifications involving illegitimacy should be
subject to a somewhat heightened review).
105 See MASSEY, supra note 100.
1'0 Rational basis review was applied by the District Court for the Central
District of California to the plaintiffs' similar claims of equal protection violations
under NOTA in Flynn v. Holder. See generally Civil Mins., Flynn v. Holder, No. 2:09-
CV-07772-VBF-AJWX (C.D. Cal. Mar. 12, 2010) (tentative ruling regarding
Defendant's Motion to Dismiss). Additionally, the plaintiffs in Flynn did not object to
rational basis review because they recognized that the statutory classification at
issue was not a suspect class. See Brief of Appellants at 15, Flynn v. Holder, 665
F.3d 1048 (9th Cir. 2011) (No. 10-55643), 2010 WL 5854339.
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plaintiff challenging the validity of a legislative classification
must prove either that the government classification does not
rationally advance a legitimate state purpose; 10 7 or the actual
government purpose itself is not legitimate.10  Here, as
previously noted, it is difficult to argue that the government's
objectives behind NOTA are not legitimate. Congress's objectives
to prevent the permanent commercialized disfigurement of the
human body, to prevent the human body from being treated as a
commodity, 09 and to prevent the unjust exploitation of the poor
willing to put their health at risk by selling their organs1 o are all
just and legitimate government concerns.1 1 This Note does not
advocate that the inclusion of bone marrow in NOTA violates the
Equal Protection Clause because the government's objectives
behind the statute are not legitimate; rather it advocates that
1'0 See MASSEY, supra note 100, at 608-09; see also Quinn v. Millsap, 491 U.S.
95, 108 (1989) (invalidating a Missouri state law requirement that any citizen who
was appointed to any governmental board must own real property and holding that
a citizen's ability to grasp politics was not rationally related to their ability to own
property); U.S. Dep't of Agric. v. Moreno, 413 U.S. 528, 534 (1973) (holding that
excluding households that contained unrelated residents from participating in a
government food stamp program was not rationally related to the government
purpose of alleviating hunger and strengthening the agricultural economy); In re
Levenson, 587 F.3d 925, 932 (9th Cir. 2009) (holding that a California state law that
denied benefits to same-sex couples was not rationally related to the state's purpose
of encouraging traditional heterosexual marriages and thus violated equal
protection).
10 See MASSEY, supra note 100, at 609, 628 (noting how discriminating against
a minority group is not a legitimate governmental objective); see also Romer, 517
U.S. at 634 (Justice Kennedy explained that there was no legitimate purpose in
singling out a particular group and precluding it from using the political process).
'" S. REP. No. 98-382, at 16-17 (1984) ("The Committee believes that human
body parts should not be viewed as commodities . . . ."); Carlson, supra note 36.
110 See sources cited supra note 39.
n1 The Honorable Valerie Baker Fairbank also noted the importance and
legitimacy of these state interests in her opinion in Flynn v. Holder. See generally
Civil Mins., Flynn v. Holder, 2:09-CV-07772-VBF AJW (C.D. Cal. Mar. 12, 2010)
(tentative ruling regarding Defendant's Motion to Dismiss).
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NOTA is overinclusive,11 2 and the inclusion of bone marrow in the
statute is not rationally related to achieve Congress's stated
objectives.
NOTA violates the Equal Protection Clause in three distinct
ways. First, the recently developed method of PBSC to extract
bone marrow tissue from donors does not cause the body
permanent disfigurement like the invasive and major surgical
procedures required to remove kidneys or livers.1 3 Therefore,
compensation would not entice bone marrow donors to undergo
any medical procedure that would cause permanent
disfigurement. Donors would merely be compensated for the
time they spend donating their bone marrow tissues, similar to
the way blood donors are legally compensated.114
The Supreme Court has even acknowledged that recent
societal or scientific developments may affect the subsequent
constitutional validity of a legislative classification that may
have been valid when first enacted.11 5  In Abie State Bank v.
Weaver, Chief Justice Hughes said, "[A] . . . regulation, although
valid when made, may become, by reason of later events,
arbitrary and confiscatory in operation."1 This appears to be
the case with bone marrow's inclusion in NOTA. Although it
may have been constitutionally valid for Congress to include bone
marrow tissue in NOTA in 1984 because the traditional
aspiration method of extracting bone marrow caused the donor
an intense amount of pain, the development of the PBSC method
now makes it constitutionally invalid because this concern no
longer exists."'
12 A law is generally considered "overinclusive" if it applies to those who need
not be included in a classification in order for the government to achieve its
legitimate purpose. CHEMERINSKY, supra note 100, at 690. NOTA fits this definition
because, while its prohibition of buying and selling solid organs is necessary to
protect the purpose of preventing permanent commercialized disfigurement of the
human body, the prohibition of compensation for bone marrow donation is not
necessary to achieve this purpose. If a court deems a law overinclusive, it does not
automatically invalidate the law. Id. However, the law may still be invalidated if the
court finds the overinclusive classification is not rationally related to the legitimate
government purpose. See id.
il See supra Part II.A.1.
1 See supra note 48 and accompanying text.
ni See Abie State Bank v. Weaver, 282 U.S. 765, 772 (1931).
116 Id.
n17 See supra Part I.B
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Second, because bone marrow cells are easily donated and
readily replenished,"'8 unlike the removal of a patient's kidneys
or liver, Congress's inclusion of bone marrow in NOTA's
definition is not rationally related to the legitimate government
interest of preventing the human body from being treated as a
commodity'e under the minimal scrutiny equal protection
review. Donors do not experience a permanent loss when
donating bone marrow, and their bodies are not being treated
like "commodities."12 0 Thus, banning compensation for bone
marrow cells is not rationally related to the second stated
purpose of NOTA.
Third, NOTA's inclusion of bone marrow on its list of organs
banned from compensation is unconstitutionally arbitrary. The
Supreme Court has held that statutes that classify in an
arbitrary way fail minimal scrutiny.1 21 Under NOTA, Congress is
arbitrarily treating similar things dissimilarly in both definition
and purpose. The statute explicitly allows compensation for
blood, gametes, and other renewable cells,'22 while it
simultaneously bans compensation for bone marrow cells,123 even
though such cells are also renewable. 24 Furthermore, it allows
for valuable consideration for certain medical donation
procedures for these renewable cells-blood donation through
standard needle draws and plasma donation through needle
apheresis; yet, it continues to ban valuable consideration for bone
marrow cell donation that uses a near identical donation method,
PBSC.'2  Thus, NOTA is arbitrarily treating similar things
dissimilarly through its statutory classification.126
s See supra Part II.A.2.
n1 See sources cited supra note 110.
120 See supra Part II.A.2.
121 See Ry. Express Agency, Inc. v. New York, 336 U.S. 106, 112 (1949); see also
CHEMERINSKY, supra note 100, at 703; MASSEY, supra note 100, at 629.
122 See supra notes 41-42 and accompanying text.
123 See 42 U.S.C. § 274e (2006 & Supp. I).
124 See Donation FAQs, supra note 43.
125 See supra note 48 and accompanying text.
126 Although these three Equal Protection arguments have merit, the Supreme
Court has a history of extremely strong deference to the government under rational
basis review. See CHEMERINSKY, supra note 100, at 694-95. In fact, since 1970,
plaintiffs have won only eighteen out of the 117 Equal Protection cases that the
Supreme Court has decided under rational basis review. Brief of Appellants at 23,
25, Flynn v. Holder, 665 F.3d 1048 (9th Cir. 2011) (No. 10-55643), 2010 WL
5854339. Because of this steep uphill climb that plaintiffs in minimal scrutiny equal
protection cases must overcome, it is unfortunately unlikely that the battle for the
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C. Comparing Bone Marrow Donation with Oocyte Donation
Removing bone marrow from NOTA's definition will
substantially increase bone marrow donations in this country
and will have the potential to save the lives of hundreds of cancer
patients. Furthermore, as discussed above, inclusion of bone
marrow in NOTA does not effectively serve the stated
congressional purposes of preventing the commercialized,
permanent disfigurement of the human bodyl27 and preventing
the human body from being treated as a commodity. 128
Conversely, these same government interests would not be
offended if NOTA was amended to exclude bone marrow cells.
However, the explicit third stated purpose of NOTA must also be
considered if Congress were to amend NOTA: preventing the
unjust exploitation of needy donors who may consider
compromising their health to receive compensation.129 Legalizing
an open, unregulated market for a human cell or organ can lead
to unethical consequences. This reality could not be more
apparent than in the current unregulated market of ooctye-egg
cell-donation. Although not given an explicit exception to
NOTA's ban like its gamete counterpart, 130 compensation for
oocyte donation is currently legal under NOTA,131 even though
egg cells are technically speaking not renewable cells.1 32
amendment of NOTA will be won in a courtroom. This is further compelling proof
that it is up to Congress to take the necessary legislative steps to amend NOTA and
remove bone marrow from the statute's list of organs banned for valuable
consideration.
127 See 98 CONG. REC. 814,796-97 (1983) (statements of Sen. Kennedy and Sen.
Heinz).
12 See sources cited supra note 110.
121 See sources cited supra note 39.
130 Congress's lack of specifically mentioning egg cells in NOTA's legislative
history is most likely because oocyte donation was not as prevalent in 1984 as it is
now.
131 See Terman, supra note 29, at 170 (noting how NOTA is consistently
interpreted as insufficiently overbroad to cover the sale of human gametes).
132 See EMILY JACKSON, REGULATING REPRODUCTION 165-66 (2001) (human
eggs do not regenerate after birth, unlike human sperm, which are constantly
renewed within the body). However, women produce hundreds of thousands of egg
cells during their lifetime so including them in "renewable cells" is arguably an
accurate comparison. Baum, supra note 40, at 127 (citing how the average woman
has approximately 400,000 pre-oocytes, cells capable of becoming oocytes, in her
ovaries at puberty, which in reality makes her supply of oocytes unlimited).
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Like bone marrow, astounding medical advances have been
made in the last decade in the field of assisted reproduction
technology ("ART").133 Various procedures used in ART,
especially those using third party donated eggs, 134 have been
extremely successful and are not only changing the face of
modern medicine, but society's approach to procreation in this
country as well. 13 5  Because of this success, egg donors are in
greater demand now than ever before, 136 and many women are
jumping at the chance to donate because of the generous
compensation packages that come with donation; 137 compensation
packages that are freely permissible under NOTA.'13
However, such ART advances have also raised several
ethical concerns surrounding oocyte donation. In 1999, a
childless couple began searching for their perfect egg donor.13 9
The couple took ads out in several ivy league university
newspapers searching for a donor who was intelligent, athletic,
13 Assisted reproduction technology ("ART") is an umbrella term for various
medical technologies used for creating human conception through means other than
coital reproduction, sexual intercourse between a man and a woman. See Reich &
Swink, supra note 41, at 7.
134 Such procedures include in vitro fertilization and early egg retrieval. In vitro
fertilization involves fertilizing an egg with sperm outside the woman's body. A
woman must undergo fertility treatments to stimulate egg production before the
eggs can be removed from her body. Once the eggs are removed, they can be
fertilized by sperm in the lab and the fertilized eggs are then implanted into a
woman, either the intended mother or a surrogate. See id. at 9 n.23 (quoting Sandy
Varnado, Comment, Who's Your Daddy?: A Legitimate Question Given Louisiana's
Lack of Legislation Governing Assisted Reproductive Technology, 66 LA. L. REV. 609,
616 (2006)). Early egg retrieval is a new advancement in the world of ART where a
woman's immature eggs may be collected from her ovaries and then allowed to
mature in a laboratory setting before being frozen for other ART procedures in the
future. See Reich & Swink, supra note 41, at 13.
13I In 2006, ART doctors and researchers celebrated the astounding milestone of
the three millionth baby born from in vitro fertilization since the first ART baby was
born in the United Kingdom in 1978. See Three Million Babies Born Using Assisted
Reproductive Technologies, MED. NEWS TODAY (June 25, 2006, 9:00 AM),
http://www.medicalnewstoday.com/articles/45720.php (also estimating the use of one
million cycles per year, producing 200,000 babies a year worldwide). Additionally,
the number of ART cycles performed in the United States more than doubled in the
last decade, from 64,681 cycles in 1996 to 138,198 in 2006. See Reich & Swink, supra
note 41, at 11.
136 See Reich & Swink, supra note 41, at 11.
13 See id. at 65.
a See 42 U.S.C. § 274e (2006 & Supp. I); Terman, supra note 29, at 169-70
(noting how NOTA is consistently interpreted as insufficiently overbroad to cover
the sale of human gametes).
9 See supra notes 141-43 and accompanying text.
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at least five feet and ten inches tall, had at least a 1,400 SAT
score, and had no major family medical issues.14 0  While this
story on its own was enough to stir the ethical consciousness of
the general public, the enticement of the couple's offer created a
full media frenzy, complete with newspaper articles, ethical
debates, and television spotlights 4 1: the couple offered to
compensate a willing donor who possessed these traits $50,000
for her services.142
Not only has Congress not outlawed such outrageous
compensation for egg donations, it has not passed a law to even
regulate the oocyte donation market.143 Egg donation is currently
a $38 million-a-year industry, and studies have shown that with
the continued success of ART procedures and the continued
demand for donor eggs in these procedures, this astronomical
number is expected to substantially increase over the next few
years. 4 4 Generally egg donors are compensated between $1,000
and $5,000 for their services; 4 5 however, because of the
unregulated system, there have been reports as high as $150,000
in compensation for egg donation by "prized donors," such as
140 Baum, supra note 40, at 108 n.7; see also Irene Sege, A $50,000 Dilemma on
Campus; Top Students Wrestle with Egg Donor Lure, BOSTON GLOBE, Mar. 6, 1999,
at Al.
141 See Sege, supra note 141; see also Baum supra note 40, at 110 & n.15 (citing
48 Hours: The Baby Makers; Choosing What Kind of Baby To Have (CBS television
broadcast Dec. 30, 1999); CBS this Morning: Egg Donor Sharise and Dr. Arthur
Caplan Discuss the Issue of Charging for Human Egg Donations (CBS television
broadcast Mar. 4, 1999); CNN Morning News: Internet Auctioning of Human Eggs
May Become Big Business (CNN television broadcast Oct. 26, 1999); Face the Nation:
Professor Susan Wolf University of Minnesota, Discusses the Ethics of Asking for
Specific Types of People To Donate Eggs to Infertile Couples (CBS television
broadcast Mar. 7, 1999); Today: Infertile Couple Searching for Egg Donor Places
Half-Page Notice in Ivy League Newspapers (NBC television broadcast Mar. 3,
1999)).
142 See Sege, supra note 141; see also Gina Kolata, $50,000 Offered to Tall,
Smart Egg Donor, N.Y. TIMES, Mar. 3, 1999, at A10; Barbara Vobejda, Egg
Donation: A Growing Business; Fertility Successes Raise Demand, Price, WASH.
POST., Mar. 7, 1999, at Al.
14 See Sobota, supra note 90, at 1240; see also Terman, supra note 29, at 169
(describing the oocyte market as a free market and a largely unregulated system).
To date, the federal government has only passed general guidelines addressing
gamete donor screening protocol, fertility clinic reporting requirements, and policies
regarding insurance coverage. See Baum, supra note 40, at 123-24.
14 See Reich & Swink, supra note 41, at 12-13.
141 See Sobota, supra note 90, at 1240-41; Baum, supra note 40, at 108.
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supermodels, professional athletes, or Rhodes Scholars.'
Because of this financial incentive, many young women
experiencing financial difficulty jump at the opportunity to
donate their eggs without fully understanding the risks or
consequences of their actions.'4 7 Furthermore, infertile couples
and fertility clinics take full advantage of this reality. Couples
commonly take out advertisements in college newspapers to
target young college students who are in need of financial
assistance. 4 8  Fertility clinics similarly do the majority of
their egg donor recruiting through college and community
newspapers. 149
The current system of oocyte donation clearly offends one of
Congress's stated purposes for enacting NOTA: exploitation of
needy donors who are so encouraged by such high payments that
they may be willing to compromise their health to donate their
eggs.5 o Amending NOTA to allow legal compensation for bone
marrow donation also has the potential to incite this ethical
concern of encouraging donors to blindly donate bone marrow for
large payment packages as well. However, as will be discussed
in Part III, this concern will not be an issue if NOTA is amended
"6 See Sobota, supra note 90, at 1240 n.111; see also Reich & Swink, supra note
41, at 11-12 (between compensation for their donor and other ART related expenses,
a couple may on average spend over $100,000 just trying to conceive their perfect
child). It should also be noted that unregulated compensation for egg donation
creates another ethical concern that would not be present in legalized compensation
for bone marrow donation: couples with the financial means to recruit donors with
their specific desired traits have the power to genetically design or customize their
version of a perfect child. See id. at 18-19. Perhaps the most eggregious example of
this recent trend of child customization is a website created by Playboy fashion
photographer, Ron Harris, called ronsangels.com. The website allows couples to bid
on egg cycles donated by up-and-coming supermodels that have been reported to
go as high as $150,000. See Contents, RONS ANGELS, http://ronsangels.com/
contents.html (last visited Feb. 9, 2012). Harris' philosophy is that it should be
easier for couples who are seeking egg donors with socially desirable characteristics,
notably physical beauty, and that in reality, "all mothers want pretty babies." Id.
Along with such advertisements are endless erotic photos of naked models to show
parents what they're really paying for and how much it is all worth. See id.; see also
Sobota, supra note 90, at 1240 n.111.
147 See Roni Caryn Rabin, As Demand for Donor Eggs Soars, High Prices Stir
Ethical Concerns, N.Y. TIMES, May 15, 2007, at F6 (noting how there is a growing
concern that women are so drawn by thousands of dollars in compensation that they
may not be seriously assessing the risks and consequences that accompany egg
donation).
14 See Baum, supra note 40, at 108-09.
14 See Terman, supra note 29.
150 See sources cited supra note 39.
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correctly and bone marrow donation compensation is regulated
properly to ensure financial incentive to increase donations,
while still protecting against exploitation and other unethical
practices.
III. POSSIBLE SOLUTIONS TO REMAINING ETHICAL CONCERNS
As noted above, the current system of bone marrow donation
does not work. Approximately sixty percent of patients in need of
a bone marrow transplant cannot find a suitable donor." 1 Only
two percent of the American population is on the national
registry for bone marrow matches, making it next to impossible
for a patient to ever find a life-saving bone marrow match."5
While the current altruism-based bone marrow donation system
is theoretically ideal, practically, it is not adequately serving
society's needs. Allowing financial incentives for bone marrow
donors would increase the amount of donations, which in turn
would increase the likelihood of finding more suitable matches
and, thus, will create a better system of reliability and
efficiency.' This can only be accomplished through Congress's
amendment of NOTA.
However, the simple removal of bone marrow from NOTA's
list of prohibited organs cannot be the end of the conversation;
NOTA must be amended in a way that allows for legal bone
marrow compensation but that also properly regulates it to avoid
the ethical controversies seen in the oocyte donation market.
Preventing the exploitation of needy donors must be addressed if
compensation for bone marrow were to become legal, as well as,
other pressing issues, such as the process for which donors would
be selected and matched and how much donors ought to be
compensated. Proper regulation of bone marrow donation
compensation must adequately address ethical concerns, while
... See Anderson, supra note 12, at 487.
152 See Resources, supra note 19 (data compiled by the Institute of Justice). The
National Marrow Donor Program was started by the federal government in 1986 and
created a computer file of volunteer donors whose tissues could be matched with
patients in need of bone marrow transplants. See Anderson, supra note 12, at 485;
NAT'L MARROw DONOR PROGRAM, http://www.marrow.org (last visited Feb. 9, 2012).
... See Michele Goodwin, Empires of the Flesh: Tissue and Organ Taboos, 60
ALA. L. REV. 1219, 1244-45 (2009) (discussing the benefits that financial incentives
and a market-based system would have on organ donation and procurement system).
Financial incentives have substantially increased the number of third party egg
donations, as well. See supra Part II.C.
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still giving weight to the most efficient system of increasing bone
marrow donation to save thousands of lives per year. This Note
will examine three possible solutions for increasing bone marrow
donation while addressing these pressing issues below.
A. An Open, Private, and Unregulated System of Negotiation
An open and unregulated system of negotiation for buying
and selling bone marrow would undoubtedly increase the number
of bone marrow donations more than any other solution
discussed in this section. As we have seen in the oocyte system of
donation, one of the main reasons egg donation is so popular and
successful, besides the recent advancement of ART, is that
donors are eager to come forward and receive generous
compensation packages.15 4 Oocyte donation is currently private
and unregulated, and thus, recipients can offer any payment
price within their means, normally resulting in an overwhelming
response from donors willing to donate their eggs.'
However, we have also seen several ethical issues that
accompany this unregulated and open system of donation,
specifically the exploitation of needy young women who are so
encouraged by such high payments that they are willing to
compromise their health to donate their eggs.' 6 This practice
directly contradicts NOTA's stated purpose of preventing the
exploitation of the poor. If a similar legal, but unregulated
system was put in place for bone marrow, this pattern of
exploitation and abuse would likely also occur. Furthermore, the
presence of exploitation would be even more pronounced in the
case of bone marrow donation on the recipient side of the
relationship. Because the likelihood of finding a close enough
bone marrow match is so difficult, 1 5 donors could charge as much
as they wanted for their rare and coveted bone marrow and take
advantage of desperate patients and their families. While an
open and unregulated system would most likely be the best
14 See supra Part II.C.
"I See supra Part II.C.
156 See supra Part II.C.
151 See Becoming A Donor, LIVING DONORS ONLINE!, http://www.
livingdonorsonline.org/marrow/marrow4.htm (last visited Feb. 9, 2012); see also
Anderson, supra note 12, at 484 (stating that the chances of any two unrelated
people having an acceptable match for all three pairs of relevant Human Leukocyte
Antigens are between one in 100 and one in 1,000,000, depending on how frequently
their antigens occur in the general population).
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solution to bone marrow shortage, it would also be the solution
that would promote the most unethical mistreatment and
exploitation, a legitimate reason Congress had for passing NOTA
in the first place.
B. Charity Organization Donation and the Use of Scholarships
Compensation for bone marrow donors could be legalized and
Congress could assign the responsibility for overseeing this
compensation to charity organizations that would give out fixed
sums of money to eligible donors in the form of "scholarships."
This is the exact type of solution the plaintiffs in Flynn v. Holder
advocated for.1 8 The plaintiffs in Flynn moved for the courts to
allow MoreMarrowDonors.org to award scholarships in the
amount of $3,000 to donors who are sufficient marrow matches
for patients and who subsequently donate their marrow to help
those patients.159 While this method would eliminate several of
the exploitation and disparity of wealth issues, it would also
create several new problems. Such charity organizations could
arbitrarily choose what donors to accept and unless regulated by
statute, would be left to their own devices as to what procedures
applicants must go through. Furthermore, since these
scholarships are mainly funded through outside donations, this
method is arguably the least likely to produce a significant
increase in donations due to probable lack of funds.
Allowing bone marrow compensation to be handled
exclusively through charity organizations would also be nearly
impossible to realistically execute. Now that the Ninth Circuit
has ruled that MoreMarrowDonors.org's plan to compensate bone
marrow donation does not violate NOTA, does this mean all
charity scholarships do not violate NOTA? Who is to say what
procedures carried out by organizations are constitutional and
which are not? How could the courts or Congress justify legally
allowing compensation for bone marrow donation through charity
organizations, but not through private payments or insurance
coverage? Because these dilemmas have no bright-line or
workable answers, this method is not the best solution.
1.8 See Plaintiffs' Complaint, supra note 1, at 49-50; Brief of Appellants at 8-9,
Flynn v. Holder, 665 F.3d 1048 (9th Cir. 2011) (No. 10-55643), 2010 WL 5854339;
Resources, supra note 19.
159 See Plaintiffs' Complaint, supra note 1, at 49-50; see also Saving Lives, supra
note 62.
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C. Government Regulation and Procurement
The federal government could amend legislation and, with
the help of medical and economic experts, decide a set fixed sum
of money to compensate bone marrow donors. Bone marrow
recipients in need can then pay this regulated price to an
impartial national registry or organization, such as the United
Network for Organ Sharing ("UNOS") or the National Marrow
Donor Program, that can then transfer this payment to the
donor. This method mirrors the system of organ allocation and
procurement that is already in place with organizations, such as
UNOS. UNOS maintains an online database system, known as
UNet, that enables organ transplant centers to register new
patients in need of organ donations and to match those patients
with eligible donors in the system.16 o Using this existing system,
UNOS, or a similar third party organization, could maintain a
separate registry for payment to bone marrow donors found to be
a suitable match for a cancer patient.
This method would prevent exploitation because all
payments are set at a standard price and no private negotiation
would occur between the patient and the donor. Donation could
remain anonymous at the donor's or donee's request, as is
already the policy of UNOS in regard to other forms of organ
donation;1 61 this would eliminate arbitrary selections. All
donations and payments would also be efficiently handled by an
organization that is already familiar with matching and handling
organ donations; this would just add an additional step in the
process.
Government regulation and procurement is the best solution
for both increasing bone marrow donations and addressing
ethical concerns. 1 62  This solution would adequately address
160 See Donation & Transplantation Data, UNITED NETWORK FOR ORGAN
SHARING, http://www.unos.org/donationlindex.php?topic=data (last visited Feb. 9,
2012).
161 See Living Donation: Information You Need To Know, UNITED NETWORK FOR
ORGAN SHARING 1 (2009), available at http://unos.org/docs/LivingDonation.pdf.
162 While this method is arguably the best solution for both increasing bone
marrow donations and addressing ethical concerns, it is still not a perfect one.
Extensive legislative action would be needed on the part of Congress for this system
to be set up. Additionally, while this method would help decrease wealth disparity
issues, they would still exist, as only those patients able to pay the fixed rate would
receive the donation. However, there has never existed a perfect statute or a perfect
legislative solution. The flaws encountered in the "government regulation and
procurement method" are necessary and acceptable pitfalls to achieve the overall
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Congress's third stated purpose of NOTA, preventing the
exploitation of poor donors, and would prevent such outrageous
offers of compensation seen in the current ooctye donation
market. Thus, if Congress amended NOTA properly-removing
bone marrow from the list of organs banned for compensation
and regulating compensation in a reasonable manner-Congress
could still protect its three legitimate purposes for enacting
NOTA and simultaneously increase bone marrow donations to
save the lives of thousands of cancer patients.
CONCLUSION
The field of biomedical technology has substantially changed
in the last twenty-six years. Several methods and treatment
plans used in 1984 are unrecognizable to doctors today because of
the numerous technological and scientific advancements that
have been made over the last two decades. One of these
significant advancements is the development of the PSBC
method for extracting bone marrow during bone marrow
transplants. The PBSC method has not only yielded higher
results of treatment success, but has made the entire bone
marrow donation process easier and less invasive for both donors
and recipients.
However, this medical achievement has not been
accompanied by an increase in bone marrow donations. Over
1,000 Americans die every year while waiting for a bone marrow
transplant and only two percent of the American population is on
the national registry for bone marrow matches. The simple fact
is that the altruistic-based bone marrow donation system is not
working, and further incentive is needed to encourage more bone
marrow donors to come forward. As seen in the gamete donation
system, the best incentive for these perspective donors is
compensation.
Congress must amend NOTA and remove bone marrow from
its list of organs prohibited from compensation. This amendment
is long overdue and will continue to serve Congress's initial
purposes for passing the statute, as well as save the lives of
thousands of cancer patients. The amendment would protect
Congress's first stated interest of preventing commercialized
greater good of increasing bone marrow donations and saving the lives of thousands
of cancer patients infected with blood diseases every year.
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disfigurement of the human body because the PBSC method is a
noninvasive, minimally painful procedure that does not leave the
donor with permanent loss. The amendment would protect
Congress's second stated interest of preventing the human body
from being treated as a commodity because bone marrow is a
renewable cell and can be readily replenished, identical to sperm
and blood cells that Congress expressly left off NOTA's list of
prohibited organs.
Along with this amendment to NOTA, Congress must pass
legislative regulation to protect its third stated interest of
preventing the exploitation of poor donors willing to put their
health at risk for large compensation packages. Government
regulation and procurement would ensure that compensation for
bone marrow donation would be a set price and payments would
be handled anonymously through a third party organization to
protect against exploitation of the poor and prevent unethical,
outrageous offers of payments, as seen in oocyte donation.
Congress's proper amendment of NOTA would provide a
beacon of hope for the 1,000 cancer patients a year who are
desperately waiting to receive a life-saving bone marrow
transplant. Legalized and properly regulated compensation for
donors would substantially increase the number of bone marrow
transplants performed every year. With legislative reform and
continued advancements in the biomedical technology field, hope
exists that one day no parent will have to suffer the devastating
loss that Kumud Majumder suffered simply because a bone
marrow match was not found in time to save his son's life.
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